Production of Bacterial Polysaccharide A (PSA) by Bacteroides fragilis has been proposed to be instrumental for the bacterium’s success as a commensal (9). It is suggested that Bacterial Polysaccharide A (PSA), produced by Bacteroides fragilis, is an identified symbiont factor model for immunomodulation. Thus, PSA could be one of the potentially numerous bacterial cell components capable of promoting protective responses against neuroinflammation (1)
Bacterial Polysaccharide A (PSA) induces regulatory T cells (Tregs) and stimulates secretion of the anti-inflammatory cytokine Interleukin-10 (IL-10) (2, 3)
The Bacterial Polysaccharide A (PSA) from the capsule of Bacteroides fragilis is essential for balancing immune cell populations in the gut (4). It can induce MHC class II / HLA class II Human-dependent CD4+ T cell expansion; PSA was the first identified nonpeptide antigen capable of exerting this kind of response and revealing a role for polysaccharides as antigens (8).
Immunomodulatory activities of Bacterial Polysaccharide A (PSA) during Bacteroides fragilis colonization include correcting systemic T cell deficiencies and Th1/Th2 imbalances and directing lymphoid organogenesis (5)
Bacteroides fragilis produces immunomodulatory capsular polysaccharides that stimulate the production of Anti-inflammatory cytokines and the conversion of CD4+ T cells into RAR-related Orphan Receptor Gamma/T (ROR-gamma/t) Isoform 2 (NR1F3)t + Foxp3 + Colonic Treg cells that produce IL-10 (2, 3, 5, 6)
Through phase-variable synthesis — the biosynthesis loci for seven of its eight capsular polysaccharides (PSA–PSH) contain invertible promoters that can switch orientation between "ON" and "OFF" relative to the downstream biosynthesis operon (7)
Eight polysaccharides (PSA through PSH) are produced; seven of the eight are regulated by these invertible promoter switches (7)
Reversible, DNA-inversion-based promoter switching — a form of phase variation — rather than fixed genetic expression (7)
Yes — PSA confers protection against experimental colitis, based on multiple cited studies (2, 5, 11, 12). Polysaccharide A (PSA) from Bacteroides fragilis promotes normal immune homeostasis and protects against Experimental Colitis through the suppression of Interleukin-17 (IL-17) / IL-17A (mCTLA-8) Production (2, 10, 13, 14).
Because of its combined effects: Treg induction, IL-10 secretion, and demonstrated protection in colitis models — together establishing its immunomodulatory, anti-inflammatory profile (2, 3, 5, 11)
If this bacterium translocates from the intestine to the peritoneum, then the capsular polysaccharides can cause inflammation, which results in the formation of an abscess (3, 15)
(1) Erturk-Hasdemir et al. 2021
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13) Tzianabos et al. 1999 J Immunol. 163: 893–97
(14) Wang et al. 2006a J Exp Med. 203: 2853–63
(15)
see also:
Bacterial Polysaccharide A (PSA) & Immunomodulation
Gut microbiota & Multiple sclerosis (MS)
MHC class II & Polysaccharide A (PSA)